Literature DB >> 19433975

PEG-interferon in acute and chronic hepatitis C: a review.

Emilio Palumbo1.   

Abstract

In patients affected by chronic hepatitis, prevention of hepatitis C virus (HCV) infection complications can be achieved by antiviral therapy based on the use of a combination of pegylated interferon (PEG-IFN) alfa-2b and ribavirin, which yields a sustained eradication of infection in 40% to 50% of cases. The aim of this review is to evaluate the efficacy of PEG-IFN alpha in the treatment of acute and chronic HCV-related hepatitis. In patients affected by acute hepatitis C, the treatment is represented by PEG-IFN alpha-2b monotherapy, and combination therapy with ribavirin produces a similar response to that with interferon monotherapy. Treatment must be started within 3 months of onset of infection (at the first evidence of HCV RNA positivity) and must be prolonged for 3 months for patients affected by genotypes 2 and 3 and for 6 months for patients with genotype 1 or 4. For patients affected by chronic hepatitis C, the first line of therapy is the combination PEG-IFN alpha-2a or alpha-2b and ribavirin. Treatment must be started only for patients with detectable serum HCV RNA and an alanine aminotransferase (ALT) value >80 IU/L (normal value, 40 UI/L); if serum HCV RNA is detectable but the ALT value is normal or <80 IU/L, the patient must be monitored every 6 months. In patients infected by genotypes 1 or 4, before treatment a histological evaluation is needed only for those aged >50 years. These patients can be treated if the infection stage is >/=2 according to the Knodell index. In patients aged <50 years, in my opinion, histological evaluation is not needed, because treatment must be started also for patients with stage 1 infection. The treatment must be prolonged for 1 year, but if after 3 months of therapy the patient is positive for serum HCV RNA, then therapy must be stopped and the patient is considered a nonresponder. In patients affected by genotypes 2 and 3, therapy must be prolonged for 6 months and a histological evaluation before treatment is not needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19433975     DOI: 10.1097/MJT.0b013e3181960819

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  8 in total

Review 1.  PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis.

Authors:  Bernd C Kieseier; Peter A Calabresi
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

2.  A potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and Dengue viruses.

Authors:  Jesse Hwang; Alfred Jiang; Erol Fikrig
Journal:  Antiviral Res       Date:  2018-12-03       Impact factor: 5.970

3.  IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms.

Authors:  Nagako Akeno; Eric P Smith; Mihaela Stefan; Amanda K Huber; Weijia Zhang; Mehdi Keddache; Yaron Tomer
Journal:  J Immunol       Date:  2011-03-14       Impact factor: 5.422

4.  Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1.

Authors:  Jing Lu; Lina Yi; Jin Zhao; Jun Yu; Ying Chen; Marie C Lin; Hsiang-Fu Kung; Ming-Liang He
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

Review 5.  Innate immune receptors drive dengue virus immune activation and disease.

Authors:  Joris Sprokholt; Leanne C Helgers; Teunis Bh Geijtenbeek
Journal:  Future Virol       Date:  2017-11-17       Impact factor: 1.831

6.  Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection.

Authors:  Ahmad M Zidan; Eman A Saad; Nasser E Ibrahim; Medhat H Hashem; Amal Mahmoud; Alaa A Hemeida
Journal:  Heliyon       Date:  2021-05-03

7.  Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial).

Authors:  Maria Patrizia Carrieri; Camelia Protopopescu; Zobair Younossi; Antoine Vilotitch; Hélène Fontaine; Ventzislava Petrov-Sanchez; Fabienne Marcellin; Fabrice Carrat; Christophe Hézode; Marc Bourlière
Journal:  Patient       Date:  2017-10       Impact factor: 3.481

8.  Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF.

Authors:  Bich Hang Do; Hyo Jeong Kang; Jung-A Song; Minh Tan Nguyen; Sangsu Park; Jiwon Yoo; Anh Ngoc Nguyen; Grace G Kwon; Jaepyeong Jang; Mihee Jang; Sunju Lee; Seoungjun So; Seongrak Sim; Kyung Jin Lee; Mark J Osborn; Han Choe
Journal:  Sci Rep       Date:  2017-07-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.